(thirdQuint)Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia.

 OBJECTIVES: - Determine the response rate of patients with myelodysplastic syndromes or chronic myelomonocytic leukemia treated with doxercalciferol.

 - Determine the toxicity profile of this drug in these patients.

 - Determine the time to progression and overall survival of patients treated with this drug.

 OUTLINE: Patients receive oral doxercalciferol daily for 12 weeks.

 Treatment continues in the absence of disease progression or unacceptable toxicity.

 PROJECTED ACCRUAL: Approximately 41 patients will be accrued for this study.

.

 Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia@highlight

RATIONALE: Doxercalciferol may improve low blood cell counts and decrease the need for blood transfusions and may be an effective treatment for myelodysplastic syndrome or chronic myelomonocytic leukemia.

 PURPOSE: Phase II trial to study the effectiveness of doxercalciferol in treating patients who have myelodysplastic syndrome or chronic myelomonocytic leukemia.

